Daniel Zapata1, Lauren E Howard1,2, Emma H Allott3,4, Robert J Hamilton5, Kenneth Goldberg6, Stephen J Freedland2,7. 1. Duke University Medical Center, Durham, North Carolina. 2. Durham Veterans Affairs Medical Center, Durham, North Carolina. 3. Department of Epidemiology, University of North Carolina, Chapel Hill, North Carolina. 4. Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina. 5. Division of Urology, Department of Surgical Oncology, University Health Network, University of Toronto, Toronto, Ontario, Canada. 6. Orlando Veterans Affairs Medical Center, Orlando, Florida. 7. Cedars-Sinai Medical Center, Los Angeles, California.
Abstract
BACKGROUND: Previously, in prostate cancer-free men, we found that statin initiation resulted in a 4.1% decline in PSA. This decline in PSA was proportional to the decline in cholesterol, suggesting a link between cholesterol and PSA levels. Whether these associations vary by race has not been explored and therefore we examined the association between pre-statin serum cholesterol and PSA in black and white prostate cancer-free men. METHODS: We conducted a retrospective, cross-sectional analysis of 1,163 men (709 white and 454 black) without prostate cancer who initiated a statin between 1994 and 2006. Linear regression was used to test the association between pre-statin serum cholesterol and PSA levels, adjusting for potential confounders and stratifying by race. RESULTS: Black men were younger, had higher low-density lipoprotein (LDL) and high-density lipoprotein (HDL) levels (both P < 0.05) and a trend toward higher total cholesterol (P = 0.063). There was no difference in PSA or year of statin prescription by race (P = 0.900 and P = 0.217, respectively). On multivariable analysis, we found a positive correlation between serum PSA and total cholesterol (P = 0.005) and LDL (P = 0.003) in white men, but no association among black men. HDL was not significantly related to PSA levels in black or white men (both P > 0.5). CONCLUSIONS: Among prostate cancer-free men about to begin a statin, pre-statin total cholesterol and LDL were correlated with PSA levels in white, but not black men. If confirmed in future studies, these findings suggest that serum cholesterol may be related to prostate biology, and that this effect may vary by race.
BACKGROUND: Previously, in prostate cancer-free men, we found that statin initiation resulted in a 4.1% decline in PSA. This decline in PSA was proportional to the decline in cholesterol, suggesting a link between cholesterol and PSA levels. Whether these associations vary by race has not been explored and therefore we examined the association between pre-statin serum cholesterol and PSA in black and white prostate cancer-free men. METHODS: We conducted a retrospective, cross-sectional analysis of 1,163 men (709 white and 454 black) without prostate cancer who initiated a statin between 1994 and 2006. Linear regression was used to test the association between pre-statin serum cholesterol and PSA levels, adjusting for potential confounders and stratifying by race. RESULTS: Black men were younger, had higher low-density lipoprotein (LDL) and high-density lipoprotein (HDL) levels (both P < 0.05) and a trend toward higher total cholesterol (P = 0.063). There was no difference in PSA or year of statin prescription by race (P = 0.900 and P = 0.217, respectively). On multivariable analysis, we found a positive correlation between serum PSA and total cholesterol (P = 0.005) and LDL (P = 0.003) in white men, but no association among black men. HDL was not significantly related to PSA levels in black or white men (both P > 0.5). CONCLUSIONS: Among prostate cancer-free men about to begin a statin, pre-statin total cholesterol and LDL were correlated with PSA levels in white, but not black men. If confirmed in future studies, these findings suggest that serum cholesterol may be related to prostate biology, and that this effect may vary by race.
Authors: Juzar Jamnagerwalla; Lauren E Howard; Emma H Allott; Adriana C Vidal; Daniel M Moreira; Ramiro Castro-Santamaria; Gerald L Andriole; Michael R Freeman; Stephen J Freedland Journal: Prostate Cancer Prostatic Dis Date: 2017-12-27 Impact factor: 5.554
Authors: Emma H Allott; Elizabeth M Masko; Alexis R Freedland; Everardo Macias; Kristine Pelton; Keith R Solomon; Elahe A Mostaghel; George V Thomas; Salvatore V Pizzo; Michael R Freeman; Stephen J Freedland Journal: Prostate Cancer Prostatic Dis Date: 2018-05-23 Impact factor: 5.554
Authors: Manuel M Garrido; José C Marta; Ruy M Ribeiro; Luís C Pinheiro; João T Guimarães Journal: J Clin Lab Anal Date: 2021-03-16 Impact factor: 2.352
Authors: George Awuku Asare; Sabina Ekua Andam; Henry Asare-Anane; Seth Ammanquah; Yvonne Anang-Quartey; Daniel K Afriyie; Iddis Musah Journal: Prostate Int Date: 2017-04-20
Authors: Xavier Ruiz-Plazas; Esther Rodríguez-Gallego; Marta Alves; Antonio Altuna-Coy; Javier Lozano-Bartolomé; Manel Portero-Otin; Joan Francesc García-Fontgivell; Salomé Martínez-González; José Segarra; Matilde R Chacón Journal: J Transl Med Date: 2019-09-09 Impact factor: 5.531